Ritlecitinib higher dose + Ritlecitinib lower dose
Phase 3Recruiting 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Severe Alopecia Areata
Conditions
Severe Alopecia Areata
Trial Timeline
Sep 10, 2025 → Jun 26, 2030
NCT ID
NCT07029828About Ritlecitinib higher dose + Ritlecitinib lower dose
Ritlecitinib higher dose + Ritlecitinib lower dose is a phase 3 stage product being developed by Pfizer for Severe Alopecia Areata. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07029828. Target conditions include Severe Alopecia Areata.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07029828 | Phase 3 | Recruiting |
Competing Products
20 competing products in Severe Alopecia Areata